MOD/MOA | vyndamax

ATTR amyloidosis is caused by TTR protein destabilization - not due to the production of TTR itself²

TTR protein plays an important role in the body - it is vital to some
biologic functions including the transport of thyroxine and retinol ³

ATTR-CM: transthyretin amyloid cardiomyopathy; MOA: mechanism of action; MOD: mechanism of disease; TTR: transthyretin.

References:

VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.

Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG1O in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285-295.

Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014;5(1):45-54.

Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036-1043.

Coelho T, Merlini G, Bulawa CE, et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016;5(1):1-25.

VYNDAMAX™ is an approved treatment that specifically targets TTR destabilization
- the cause of disease pathogenesis - and fortifies the TTR tetramer to protect its
natural role³

ATTR-CM: transthyretin amyloid cardiomyopathy; MOA: mechanism of action; MOD: mechanism of disease; TTR: transthyretin.

References:

VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.

Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neural, Neurosurg Psychiatry. 2015;86(9):1036-1043.

Monteiro C, Martins da Silva A, Ferreia N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p. TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120-128.

Maurer MS, Elliott P, Merlini G, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017;10(6):e003815.

Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629-9634.

Dosing